Dr. Tan-Chiu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
12902 Usf Magnolia Dr
Tampa, FL 33612Phone+1 866-837-4112Fax+1 954-582-1860
Summary
- Elizabeth Tan-Chiu, M.D. - Board Certified Internal Medicine and Medical Oncology
As a cancer specialist, Dr. Tan-Chiu has devoted her entire medical career to Breast and Ovarian Cancer providing compassionate patient care and innovative research by making significant contributions to new and better therapies.
Dr. Tan-Chiu is a cum laude graduate of the University of the Philippines with a major in biology. In 1986, she graduated from Far Eastern University Medical School in Manila, Philippines and completed her residency in Internal Medicine at the University of Massachusetts Memorial Medical Center in Worcester, Massachusetts. She completed her fellowship training in Hematology and Medical Oncology at the University of Pittsburgh Medical Center. After that, she worked as a hematologist-oncologist for the Erie Veterans Association.
• Dr. Tan-Chiu was an Assistant Professor at the Medical College of Pennsylvania-Hahnemann.
• She also served as the Associate-Director of Medical Oversight for the National Surgical Adjuvant Breast and Bowel Project (NSABP), an NCI-funded organization that has been conducting clinical trials in breast and colorectal cancer for over forty years.
• She was instrumental in writing NSABP's adjuvant clinical trial involving Herceptin© - Trastuzumab and has published numerous journal articles in the adjuvant therapy and prevention of breast cancer.
• She served as Associate Director of Cancer Research Network.
• She is currently the Medical Director of Florida Cancer Care and Research Director of Florida Cancer Research Institute.
Education & Training
- UPMC Medical EducationFellowship, Hematology and Medical Oncology, 1992 - 1995
- UMass Chan Medical SchoolResidency, Internal Medicine, 1989 - 1992
- Far Eastern University Nicanor Reyes Medical FoundationClass of 1986
Certifications & Licensure
- CA State Medical License 1992 - 2026
- FL State Medical License 1997 - 2026
- GU State Medical License Active through 2025
- PA State Medical License 1993 - 2010
- American Board of Internal Medicine Medical Oncology
- Hematology & OncologyHematology & Oncology
Awards, Honors, & Recognition
- Associate-Director of Medical Oversight National Surgical Adjuvant Breast and Bowel Project (NSABP)
- Associate Director Cancer Research Network, Plantation, FL
- Medical and Research Director Florida Cancer Research Institute
Clinical Trials
- Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence Start of enrollment: 2011 Nov 01
- Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer Start of enrollment: 2013 Mar 01
- Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer Start of enrollment: 2013 Sep 06
- Join now to see all
Publications & Presentations
PubMed
- 8 citationsSapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer.Bora Lim, David Potter, Mohamad Adham Salkeni, Paula Silverman, Tufia C. Haddad
Clinical Cancer Research. 2021-04-05 - 46 citationsPF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, do...Mark D. Pegram, Igor Bondarenko, Marina Moreira Costa Zorzetto, Sachin Hingmire, Hirotaka Iwase
British Journal of Cancer. 2019-01-01 - 376 citationsNeratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3...Miguel Martin, Frankie A. Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy
The Lancet. Oncology. 2017-12-01
Press Mentions
- Holy Cross Health Adds Two Oncologists/HematologistsJuly 19th, 2021
Professional Memberships
- Member
- Member
Other Languages
- Chinese (Mandarin), Tagalog, Spanish, Hindi, Gujarati, Urdu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: